Although oncogenic HRAS and KRAS mutations are most frequently found in epithelial cell-derived adenocarcinomas, their impacts have been discussed primarily on the basis of the fibroblast phenotype in the field of aging and cancer biology. This evidence concerns the gene KRAS and cancer.